A Phase 1/2 interventional study of Met DR in Type 2 Diabetes Mellitus, sponsored by Elcelyx Therapeutics, Inc.. Completed. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2016-10-21.
Sponsored by Elcelyx Therapeutics, Inc. · Phase 1/2, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 236th largest by enrollment of the 287 interventional ones that give a count, is one of 23 that started in 2012, is one of 3 in phase 1/2, and was the 172nd registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 23 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 26 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
Elcelyx Therapeutics, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Elcelyx Therapeutics, Inc. has 4 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study compared the effects of delayed-release metformin (Met DR, EFB0027) administered once daily in the morning (qAM), administered once daily in the evening (qPM), and administered twice daily (BID) on circulating glucose concentrations and metformin pharmacokinetics (PK) in subjects with type 2 diabetes mellitus (T2DM).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Was diagnosed with type 2 diabetes mellitus with
between 6.0 to 9.5% (inclusive) for subjects managing their diabetes with:
i. Diet and exercise alone, or ii. A stable regimen (minimum of 2 months at Visit 1) of metformin alone, or iii. A stable regimen (minimum of 2 months at Visit 1) of DPP-4 inhibitor alone OR
Male, or if female and met all of the following criteria:
Exclusion Criteria:
Had a medical condition that could potentially affect study participation and/or personal well-being, as judged by the investigator, including but not limited to the following conditions:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two doses of 500 mg metformin delayed-release
Drug: Met DR
One dose of 1000 mg metformin delayed-release in the morning
Drug: Met DR
One dose of 1000 mg metformin delayed-release in the evening
Drug: Met DR
metformin delayed-release tablets
Also known as: EFB0027
AUC (0-24) of Plasma Metformin
AUC (0-24) = Area under the curve from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.
Time frame: Times points to create the AUC (0-24) were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.
Cmax of Plasma Metformin
Cmax = maximum response from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.
Time frame: Times points to determine Cmax were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 19, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.
AUC (0-24) of Plasma Glucose
AUC (0-24) = Area under the curve from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.
Time frame: Times points to create the AUC (0-24) were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.75, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 18.5, 19, 19.5, 20, 21, 22, 23, and 24 hours relative to the time of the standardized dinner.
Rmax (0-24) of Plasma Glucose
Rmax (0-24) = maximum response from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.
Time frame: Times points to determine Rmax were: t = -0.08, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, 10, 11, 11.75, 11.92, 12.5, 13, 13.5, 14, 14.5, 15, 16, 17, 18, 18.5, 19, 19.5, 20, 21, 22, 23, and 24 hours relative to the start time of the standardized dinner.
| Milestone | Sequence 1: ABC | Sequence 2: BCA | Sequence 3: CAB |
|---|---|---|---|
| Started | 9 | 8 | 9 |
| Completed treatment a | 9 | 6 | 8 |
| Completed treatment b | 8 | 8 | 8 |
| Completed treatment c | 7 | 7 | 9 |
| Completed | 6 | 6 | 8 |
| Not completed | 3 | 2 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 |
| Withdrew: Non-compliance | 1 | 1 | 0 |
| Withdrew: Personal reason | 0 | 0 | 1 |
AUC (0-24) = Area under the curve from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.
| ng*h/mL | 500 mg Met DR BID | 1000 mg Met DR qAM | 1000 mg Met DR qPM |
|---|---|---|---|
| AUC (0-24) of Plasma Metformin | 7771 ± 619 | 5559 ± 433 | 7757 ± 604 |
Cmax = maximum response from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.
| ng/mL | 500 mg Met DR BID | 1000 mg Met DR qAM | 1000 mg Met DR qPM |
|---|---|---|---|
| Cmax of Plasma Metformin | 780 ± 71.7 | 868 ± 79.8 | 1035 ± 95.2 |
AUC (0-24) = Area under the curve from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.
| mg*h/dL | 500 mg Met DR BID | 1000 mg Met DR qAM | 1000 mg Met DR qPM |
|---|---|---|---|
| Pre-Treatment | 4668 ± 581 | 4947 ± 615 | 4961 ± 617 |
| On-Treatment | 4438 ± 552 | 4503 ± 560 | 4509 ± 561 |
Rmax (0-24) = maximum response from the start time of the standardized dinner (0 h) to 24 hours after the standardized dinner. Study medication was administered at t = 0 hours for Treatments B and C and at t = 12 hours for Treatments A and C.
| mg/dL | 500 mg Met DR BID | 1000 mg Met DR qAM | 1000 mg Met DR qPM |
|---|---|---|---|
| Pre-Treatment | 279 ± 29.9 | 290 ± 31.1 | 302 ± 32.4 |
| On-Treatment | 263 ± 28.2 | 262 ± 28.1 | 273 ± 29.4 |
Collected over Approximately 36 to 91 days depending on the number of days between the start of Visit 1 and Visit 2 and the number of washout days between the treatment periods.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1000 mg Met DR qAM | — | 0/23 (0%) | 6/23 (26.1%) |
| 1000 mg Met DR qPM | — | 0/24 (0%) | 5/24 (20.8%) |
| 500 mg Met DR BID | — | 0/23 (0%) | 7/23 (30.4%) |
| Event | 1000 mg Met DR qAM | 1000 mg Met DR qPM | 500 mg Met DR BID |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/23 | 0/24 | 1/23 |
| NauseaGastrointestinal disorders | 0/23 | 0/24 | 2/23 |
| VomitingGastrointestinal disorders | 0/23 | 0/24 | 2/23 |
| Vessel Puncture Site PainGeneral disorders | 1/23 | 0/24 | 2/23 |
| PalpitationsCardiac disorders | 0/23 | 0/24 | 1/23 |
| Abdominal PainGastrointestinal disorders | 0/23 | 0/24 | 1/23 |
| Breath OdourGastrointestinal disorders | 1/23 | 0/24 | 1/23 |
| Dry MouthGastrointestinal disorders | 0/23 | 0/24 | 1/23 |
| FatigueGeneral disorders | 0/23 | 1/24 | 1/23 |
| Vessel Puncture Site SwellingGeneral disorders | 0/23 | 0/24 | 1/23 |
Randomized (ITT) Population
| Age, Continuous(years) | Sequence 1: ABC | Sequence 2: BCA | Sequence 3: CAB | Total |
|---|---|---|---|---|
| Mean | 51.2 ± 11.73 | 51.9 ± 13.47 | 49.7 ± 8.49 | 50.9 ± 10.90 |
| Sex: Female, Male(Participants) | Sequence 1: ABC | Sequence 2: BCA | Sequence 3: CAB | Total |
|---|---|---|---|---|
| Female | 6 | 6 | 4 | 16 |
| Male | 3 | 2 | 5 | 10 |
| Ethnicity (NIH/OMB)(Participants) | Sequence 1: ABC | Sequence 2: BCA | Sequence 3: CAB | Total |
|---|---|---|---|---|
| Hispanic or Latino | 7 | 6 | 5 | 18 |
| Not Hispanic or Latino | 2 | 2 | 4 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence 1: ABC | Sequence 2: BCA | Sequence 3: CAB | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 | 2 |
| White | 8 | 8 | 8 | 24 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| BMI(kg/m^2) | Sequence 1: ABC | Sequence 2: BCA | Sequence 3: CAB | Total |
|---|---|---|---|---|
| Mean | 32.3 ± 3.73 | 31.6 ± 3.93 | 30.7 ± 1.58 | 31.5 ± 3.17 |
| Diabetes Management(participants) | Sequence 1: ABC | Sequence 2: BCA | Sequence 3: CAB | Total |
|---|---|---|---|---|
| Diet and Exercise Only | 1 | 4 | 2 | 7 |
| Metformin Alone | 7 | 3 | 7 | 17 |
| Metformin and DPP-4 Inhibitors | 1 | 1 | 0 | 2 |
| Fasting Serum Glucose(mg/dL) | Sequence 1: ABC | Sequence 2: BCA | Sequence 3: CAB | Total |
|---|---|---|---|---|
| Mean | 161.2 ± 29.94 | 177.6 ± 84.17 | 165.0 ± 54.02 | 167.6 ± 57.04 |
| HbA1c(%) | Sequence 1: ABC | Sequence 2: BCA | Sequence 3: CAB | Total |
|---|---|---|---|---|
| Mean | 7.34 ± 1.038 | 7.13 ± 1.107 | 7.36 ± 1.022 | 7.28 ± 1.017 |
No study locations are listed for this record.
The record gives a start of Dec 2012, a primary completion of Apr 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2016, 3 years after primary completion. A results delay was requested in Aug 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Elcelyx Therapeutics, Inc.